Imperial College London
Portrait Picture

DrJonathanKrell

Faculty of Medicine, Department of Surgery & Cancer

Clinical SL in Medical Oncology (Gynaecological Oncology)
 
 
 
//

Contact

 

j.krell

 
 
//

Location

 

Institute of Reproductive and Developmental BiologyHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{McNeish:2020,
author = {McNeish, I and Morgan, RD and Cook, AD and James, EC and Lord, R and Dark, G and Glasspool, RM and Krell, J and Parkinson, C and Poole, CJ and Hall, M and Gallardo-Rincón, D and Lockley, M and Essapen, S and Summers, J and Anand, A and Zachariah, A and Williams, S and Jones, R and Scatchard, K and Walther, A and Kim, J-W and Sundar, S and Jayson, GC and Ledermann, JA and Clamp, AR},
journal = {The Lancet Oncology},
title = {An exploratory analysis of objective responses to neoadjuvant chemotherapy: results from a randomised phase III trial evaluating first-line carboplatin-paclitaxel regimens for ovarian, fallopian tube or primary peritoneal carcinoma (ICON8)},
url = {http://hdl.handle.net/10044/1/83730},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundPlatinum-based neoadjuvant chemotherapy (NACT) followed by delayed primary surgery (DPS) is an established strategy for women with newly diagnosed, advanced stage epithelial ovarian cancer. Although this therapeutic approach has been validated in randomised, phase III trials,evaluation of response to NACT using Response Evaluation Criteria in Solid Tumours (RECIST)and CA125 was not reported. We describeRECIST and Gynecologic Cancer InterGroup (GCIG)CA125 responses in patients receiving platinum-based NACT followed by DPS in the phase III trial, ICON8.MethodsICON8 was an international, multicentre, randomised, phase III trial in which women ≥18 years old with an Eastern Cooperative Oncology Group performance status of 0-2, life expectancy >12 weeks and newly diagnosed International Federation of Gynecology and Obstetrics (FIGO;1988) stage IC-IIA high-grade serous, clear cell or any poorly differentiated/grade 3 histological subtype or any FIGO (1988) stage IIB-IV epithelial cancer of the ovary, fallopian tube or primary peritoneum were randomised (1:1:1) to receive either intravenous (IV) carboplatin (AUC5/6)and IV paclitaxel (175mg/m2by body surface area [BSA])on day 1 of every 21-day cycle(control arm)or IV carboplatin (AUC5/6)on day 1 and IV paclitaxel (80mg/m2by BSA)on days 1, 8 and 15 of every 21-day cycle(dose-fractionated paclitaxelarm) or IV carboplatin (AUC2)and IV paclitaxel (80mg/m2by BSA)on days 1, 8 and 15 of every 21-day cycle(dose-fractionated carboplatin and paclitaxelarm). Randomisation occurred using a minimisation method and patients where stratified according to GCIG group, disease stage and timing and outcome of cytoreductive surgery. Neither patients nor clinicians were masked to their allocated group. The scheduling of surgery and use of NACTwere determined by local multidisciplinary case review. In this post-hoc 5exploratory analysis of ICON8, progression-free survival (PFS) was analysed using the landmark method and defined as
AU  - McNeish,I
AU  - Morgan,RD
AU  - Cook,AD
AU  - James,EC
AU  - Lord,R
AU  - Dark,G
AU  - Glasspool,RM
AU  - Krell,J
AU  - Parkinson,C
AU  - Poole,CJ
AU  - Hall,M
AU  - Gallardo-Rincón,D
AU  - Lockley,M
AU  - Essapen,S
AU  - Summers,J
AU  - Anand,A
AU  - Zachariah,A
AU  - Williams,S
AU  - Jones,R
AU  - Scatchard,K
AU  - Walther,A
AU  - Kim,J-W
AU  - Sundar,S
AU  - Jayson,GC
AU  - Ledermann,JA
AU  - Clamp,AR
PY  - 2020///
SN  - 1213-9432
TI  - An exploratory analysis of objective responses to neoadjuvant chemotherapy: results from a randomised phase III trial evaluating first-line carboplatin-paclitaxel regimens for ovarian, fallopian tube or primary peritoneal carcinoma (ICON8)
T2  - The Lancet Oncology
UR  - http://hdl.handle.net/10044/1/83730
ER  -
Download